Investigation of evolved paraoxonase-1 variants for prevention of organophosphorous pesticide compound intoxication

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 3, 2014, Pages 549-558

  Mata, David G ^a   Rezk, Peter E ^a,b   Sabnekar, Praveena ^a   Cerasoli, Douglas M ^a   Chilukuri, Nageswararao ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; ORGANOPHOSPHATE PESTICIDE; PARAOXON; SCAFFOLD PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LD 50; MALE; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; ORGANOPHOSPHATE POISONING; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; STOICHIOMETRY; SURVIVAL RATE; TREMOR;

ADENOVIRIDAE; ANIMALS; ARYLDIALKYLPHOSPHATASE; BIOCATALYSIS; ESCHERICHIA COLI; GENE TRANSFER TECHNIQUES; GENETIC VARIATION; GENETIC VECTORS; HEK293 CELLS; HUMANS; LETHAL DOSE 50; MALE; MICE; ORGANOPHOSPHATE POISONING; PESTICIDES; PROTEIN ENGINEERING;

EID: 84901197066     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.213645     Document Type: Article

References (34)

1. Aldridge WN and Davison AN (1953) The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem J 55:763-766.
2. Allon N, Raveh L, Gilat E, Cohen E, Grunwald J, and Ashani Y (1998) Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci 43:121-128.
3. Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP, and Raveh L (1991) Butyr-ylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 41:37-41.
4. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, and La Du B (1998) Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18:1617-1624.
5. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, and Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
6. Dirnhuber P, French MC, Green DM, Leadbeater L, and Stratton JA (1979) The protection of primates against soman poisoning by pretreatment with pyr-idostigmine. J Pharm Pharmacol 31:295-299.
7. Doctor BP and Saxena A (2005) Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157-158:167-171.
8. Draganov DI and La Du BN (2004) Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369:78-88.
9. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, and La Du BN (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239-1247.
10. Duysen EG, Parikh K, Aleti V, Manne V, Lockridge O, and Chilukuri N (2011) Adenovirus-mediated human paraoxonase1 gene transfer to provide protection against the toxicity of the organophosphorus pesticide toxicant diazoxon. Gene Ther 18:250-257.
11. Gaidukov L and Tawfik DS (2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44:11843-11854.
12. Gaidukov L, Viji RI, Yacobson S, Rosenblat M, Aviram M, and Tawfik DS (2010) ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry 49:532-538.
13. Geyer BC, Kannan L, Garnaud PE, Broomfield CA, Cadieux CL, Cherni I, Hodgins SM, Kasten SA, Kelley K, and Kilbourne J, et al. (2010) Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents. Proc Natl Acad Sci USA 107: 20251-20256.
14. Goldsmith M, Ashani Y, Simo Y, Ben-David M, Leader H, Silman I, Sussman JL, and Tawfik DS (2012) Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. Chem Biol 19:456-466.
15. Gordon SM, Deng J, Lu LJ, and Davidson WS (2010) Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatog-raphy. J Proteome Res 9:5239-5249.
16. Gupta RD, Goldsmith M, Ashani Y, Simo Y, Mullokandov G, Bar H, Ben-David M, Leader H, Margalit R, and Silman I, et al. (2011) Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. Nat Chem Biol 7:120-125.
17. Hardman JG, Limbird LE, and Gilman AG (2001) Anticholinesterase Agents, McGraw-Hill, New York.
18. Hodgins SM, Kasten SA, Harrison J, Otto TC, Oliver ZP, Rezk P, Reeves TE, Chilukuri N, and Cerasoli DM (2013) Assessing protection against OP pesticides and nerve agents provided by wild-type HuPON1 purified from Trichoplusia ni larvae or induced via adenoviral infection. Chem Biol Interact 203:177-180.
19. Khersonsky O and Tawfik DS (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44:6371-6382.
20. Kuo CL and La Du BN (1995) Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos 23:935-944.
21. Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM, Federko JM, Luo C, Saxena A, and Doctor BP, et al. (2005) Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 157-158:205-210.
22. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, and Furlong CE (2000) Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767-779.
23. Lusis AJ (2000) Atherosclerosis. Nature 407:233-241.
24. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shih D, and Fonarow GC (1998) Paraoxonase and coronary heart disease. Curr Opin Lipidol 9:319-324.
25. Moren X, Deakin S, Liu ML, Taskinen MR, and James RW (2008) HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress. J Lipid Res 49:1246-1253.
26. Parikh K, Duysen EG, Snow B, Jensen NS, Manne V, Lockridge O, and Chilukuri N (2011) Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. J Pharmacol Exp Ther 337:92-101.
27. Raveh L, Grauer E, Grunwald J, Cohen E, and Ashani Y (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 145:43-53.
28. Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, and Ashani Y (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 45: 2465-2474.
29. Rezk PE, Zdenka P, Sabnekar P, Kajih T, Mata DG, Wrobel C, Cerasoli DM, and Chilukuri N (2014) An in vitro and in vivo evaluation of the efficacy of recombinant human liver prolidase as a catalytic bioscavenger of chemical warfare nerve agents. Drug Chem Toxicol DOI:10.3109/01480545.2014.900071.
30. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, and La Du BN (1999) Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19:2214-2225.
31. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, and Furlong CE (2008) Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc Natl Acad Sci USA 105:12780-12784.
32. Stewart WC and Anderson EA (1968) Effect of a cholinesterase inhibitor when injected into the medulla of the rabbit. J Pharmacol Exp Ther 162:309-318.
33. WHO (1986) Informal Consultation on Planning Strategy for the Prevention of Pesticide Poisoning, World Health Organization, Geneva.
34. WHO (1990) Public Health Impact of Pesticides Used in Agriculture, World Health Organization, Geneva.